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ABSTRACT 
 
Hamad, Yasser, M., Masters of Public Health: June: 2019], Public Health  
Title: Incidence of Chronic Myeloid Leukemia: Systematic Review and Meta-analysis  
Supervisor of Thesis: Ula, Middle Initial, Nur. 
Background: To systematically assess and review the global incidence of Chronic 
Myeloid Leukemia using meta analyses and explore the factors associated with the 
variation of incidence of CML. 
Methods: Observational studies reporting CML from the globe were systematically 
searched in databases including MEDLINE (Ovid) and ProQuest. The author screened 
the studies and extracted data and assessed the risk of bias. Hoy’s risk of Bias tool 
was used to assess the biases in individual studies. 
Results: Seven studies reporting CML Incidence were included. pooled estimate of 
the CML incidence were 0.92 per 100,000 populations (95% CI: 0.70 – 1.22), 
Subgroup analysis shows no significant regional variation between Europe vs other 
country and global estimate. There was no trend when CML plotted over time.  
 Conclusion: Given the pooled estimates vary widely with substantial heterogeneity, 
larger, well-designed studies especially in region and countries of developing world 
(Asia and Africa) are warranted to better understand the frequency and burden of 
CML. 
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Chapter 1: Introduction 
 
1.1 Background 
 
            Chronic Myeloid Leukemia (CML) is a form of malignancy that affects the 
bone marrow and blood and characterized by high production of white cells 
named granulocytes [1]. these malignant cells (called blasts or leukemic blasts) slowly 
crowd the bone marrow and preventing the production non- malignant blood cell [1].                                            
CML is associated with the fusion of two genes: BCR (on chromosome 22) and ABL1 
(on chromosome 9) resulting in the BCR-ABL1(Break Cluster Region-Abelson) 
fusion gene. This abnormal fusion typically results from a reciprocal translocation 
between chromosomes 9 and 22, t (9;22) (q34; q11), that gives rise to an abnormal 
chromosome 22 called the Philadelphia (Ph) chromosome. It is this derivative 
chromosome 22 which harbors the BCR-ABL1 fusion gene [2]. figure 1. 
 
 
 
Figure 1. Normal chromosome vs translocated one.  
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            CML patients are at increased risk of several Consequences and health 
problems; infectious complications, for example, are happening due to weakened 
immune system which may result in more severe complication [3]. Furthermore, some 
treatments used to manage CML can lead to infertility; Chang et al propose that 
Tyrosine Kinase Inhibiters(TKIs) passes the testis- blood barrier and decreases sperm 
thickness, sperm numbers, and movement [4]. The etiology of CML is largely 
unknown. The only deep-rooted predictor and risk factor is exposure to high doses of 
ionizing radiation, reported by Hsu WL et al in Japanese survivors following atomic 
attack in Hiroshima and Nagasaki [5]. 
            Incidence of CML has been reported to vary widely between registries and 
countries. It is not clear if the global incidence is increasing and if certain populations 
are more affected than the others. However, Rohrbacher issued a study approximate 
CML incidence from 1 to 2 cases per 100 000 people every year [6]. Same study 
reported an example of France to show how CML prevalence changed over years and 
especially after introducing of Imatinib from 4.1% during 1998 to 2002 and of 9.3% 
during 2003 to 2007[7].  
            CML is more common in males than in females, it can happen in all age levels 
but is predominantly a disease of older population, accounting for 15% of all adult 
Leukemia’s [6].  Although, it is commonly defined to take place in late adulthood, the 
median age varies among registries beginning the late 30’s up to 65 years [8]. There is 
no solid evidence to suggest a particular ethnicity is more likely be affected, in spite 
of some reports of lower incidence rates in several Asian populations [9, 10].  
            CML treatment proceeded broadly after Imatinib was initially introduced in 
1996 as a (TKI) with High specificity against BCR–ABL fused gene [11]. 
Consequently, CML survival rates have enhanced radically to provide a life 
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expectation near that of the Normal non-diseased population [12]. Alongside, its 
prevalence has increased in the last years and the necessity of nonstop TKI treatment 
in most cases is debatable and will have an influence on forthcoming healthcare 
related expenditure [10].  
            In order to cover the knowledge gap of Incidence variation over registries, and 
identify factors that may affect this variation. Our study aiming to assess 
systematically the global incidence of CML and quantify it and explain possible 
caused for variation based on time and geographical differences. Systematic Review 
and Meta-analysis was performed to locate all relevant studies that reported CML 
incidence under any time period and any population being studied. After collecting all 
studies, appropriate tool used to judge risk of bias and give consequent quality score. 
Then, estimations pooled and assessed for heterogeneity and publication bias. 
           
 
1.2 Aims: 
 
 To systematically review the global incidence of CML  
 To quantify the global incidence of CML using meta analyses 
 To explore the factors associated with the variation of incidence of CML. 
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Chapter 2: Literature Review 
 
2.1 CML: Incidence, Prevalence and Burden 
 
            CML is a relatively rare disease as per WHO definition of rare diseases. The 
incidence of CML varies between different countries, populations and age groups. For 
instance, a recent, larger study form the USA reported an incidence of as high as 1.75 
per 100,000 persons, while a Chinese study reported a somewhat lower incidence of 
0.4 per 100 000 persons [14, 15]. According to the study "The global incidence and 
prevalence of chronic myeloid leukemia over the next ten years (2017-
2027)", incidence of CML in Europe differ than other region with 1,4 100 000 
persons and the prevalence, 11 cases per 100 000 persons in 2017[15]. CML is even 
rarer in children with an annual incidence of 0.06–0.12 per 100,000 children [16].   
            The fluctuation in rate continued to prevalence. For example, Visser et al. 
reported a prevalence of 5.6 per 100 000 persons in Europe in 2008 [17]. 
Approximately 70 000 persons, corresponding to 22.7 per 100 000 persons, suffer 
from CML in USA today which is expected to increase to 112 000 in 2020, 144 000 
in 2030, 167 000 in 2040, and 181 000 in 2050, when it is expected to reach a plateau 
[18]. In Sweden, Ohm et al. have observed a prevalence of CML of 9.2 per 100 000 
inhabitants in 2008, which is by 2050 expected to increase to 17 per 100 000 persons 
[19].  
CML is also reported to have slight male dominance with a number of studies 
presenting males are more plausible affected than females. For instance, a recent 
Swedish study showed the male / female ratio of CML to be 1.2:1 [10].  Median age 
of the CML also appear to vary based on population and registries.  More importantly 
population structure in the countries would also have an impact on this.  
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CML places a financial burden on patients that is associated with patients 
taking measures that may considerably affect quality of life and may adversely impact 
treatment outcomes. Quality of Life (QoL) in CML patient on long-term tyrosine 
kinase inhibitors therapy overall report QoL similar to that of the general population, 
the era of tyrosine kinase inhibitors has transformed CML from an often fatal disease 
to one with an excellent prognosis. The increasing burden is due to several factors, 
including population growth and ageing as well as the changing prevalence. With 
ongoing treatment, several patients living with CML may have to be able to cope with 
a substantial monetary burden associated with care, including medication payment 
and care expenditure, and other out of pocket costs [20]. 
 
2.2 CML:  Management and Phases 
            CML was in the pre-TKI era a disease associated with poor prognosis and a 
short survival time, although a small number of younger patients were cured by bone 
marrow transplantation, the latter associated with considerable treatment related 
mortality and morbidity [21-22]. With the introduction of the TKI (Imatinib) in the 
early 2000s, the survival has rapidly increased and is currently pushing a 5-year 
relative and overall survival (OS) of nearly 90 % [23-24].  
 
2.2.1 Treatment options: 
            Therapy choices for patients with chronic myeloid leukemia (CML) be 
determined by the stage of disease (chronic, accelerated, or blast phase), age at 
diagnosis, extra predictive features. 
            The introduction of Imatinib revolutionized CML treatment by inhibiting the 
BCR-ABL gene of the t (9;22) chromosomal translocation forming acute lymphocytic 
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leukemia and the Philadelphia chromosome characteristic of CMLs [25]. Imatinib is a 
first generation TKI that minimally inhibits BCR-ABL as compared to Dasatinib and 
Nilotinib. Imatinib also inhibits platelet-derived growth factor receptors at 
concentrations that are clinically relevant [26].  
            Fusing BCR and ABL creates a constitutive ABL tyrosine kinase that 
transforms hematopoietic progenitor cells. Imatinib was approved in 2002 to treat 
CML based on long-term efficacy, high molecular and cytogenetic response rates, and 
superior intolerability over therapies based on interferon [26].  
            Imatinib is a standard therapy for diagnosing CML in patients at the chronic 
phase and those who fail stem cell transplants or interferon therapies. Imatinib 
became a model for targeted cancer treatments [27]. Strategies for treating patients 
who resist Imatinib include dose escalation or adjusted pharmacokinetics using novel 
tyrosine kinase inhibitors. 
            Nilotinib and Dasatinib are used to treat patients who resist therapies such as 
Imatinib [10]. Nilotinib and Dasatinib were approved as clinically effective even 
though they exhibit differential safety profiles.  
            However, adherence to therapy, concomitant medications, dosing schedules 
for therapy, differential pharmacokinetic profiles, and mutation status should be 
considered in the decision-making processes. 
 
2.2.1.2 Disease Phases: 
            CML is categorized into three groups that help predict the outlook of the 
disease. Different experts suggest different cut-offs for defining the phases, but the 
system of the World Health Organization is widely adopted [28]. 
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2.2.1.2.1 Chronic phase 
            The bone marrow and blood of patients at the chronic phase has 10% blasts. 
The patients often exhibit mild symptoms that are easily treated using standard drugs 
[29]. Most diagnosis often occurs at the chronic phase.  
 
2.2.1.2.2 Accelerated phase 
            The bone marrow and blood of patients at the accelerated phase have 15% 
blasts but no more than 30% [30]. Basophils account for 20% or more of their blood 
while the blasts make up approximately 30% of their blood. Low platelet counts not 
exceeding 100 x 1,000/mm3 and with no relation to treatment is evident [31]. 
Chromosomal changes in leukemia cells are also evident in patients with the 
Philadelphia chromosome. 
 
2.2.1.2.3 Blast phase 
            The bone marrow and blood of patients at the blast phase have 20 % or more 
blasts. Large blast clusters are evident in the bone marrow, from which they spread to 
tissues and organs [32]. The phase acts like acute leukemia with most patients losing 
their weight and appetites and having fevers. 
 
2.2.1.3 TKI Cessation: 
            CML treatment showed favorable result dramatically changed outcomes 
especially in patients in the chronic phase since the releasing of  first and Second 
generation of TKIs in 2001and 2007 respectively [33]. Patients with this traditionally 
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lethal illness today experiencing survival similar to the general people [34]. Although 
it was firstly thought that TKI treatment must be persistent forever, it is nowadays 
well believed that a smaller group of patients who reach a deep and sustained 
molecular response (DMR) can efficaciously cease TKI therapy and sustain a 
treatment-free remission (TFR). This was primary proven in the STIM1 trial [35]. 
Termination of treatment in trial sites seems to not cause harm with the mainstream of 
patients who didn’t succeed to keep a TFR retrieval a DMR after months of resuming 
TKIs. One patient only expired to date after converting to progressive phase disease 
among 2500 patients reported. The ununiformed trial standards and outcomes raises a 
number of obstacles to outline criteria for the suitable and safe time to halt TKI 
therapy in general practice. 
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Chapter 3: Methods:  Systematic review and Meta-analysis 
 
3.1 Prisma 
 
            The recommendations from the Preferred Reporting Items for Systematic 
Review and Meta-Analysis (PRISMA) were used as a guide for reporting this 
systematic review and meta-analysis [36].  
 
3.2 Inclusion Criteria 
 
            Eligible studies for this systematic review included the confirmed cases of 
CML in cohort or population-based studies of patients including case series and 
registry data. Both prospective and retrospective studies were included. Studies 
reporting the number, frequency or incidence of Chronic Myeloid Leukemia in any 
age along with appropriate denominator were included. Studies that reported any form 
of incidence like the crude one, age standardized or per person year will be included. 
In addition to studies that reported data on subgroups of patients were also included 
like CML with positive BCR/ABL or CML with negative BCR/ABL.  
 
3.3 Exclusion Criteria 
 
Randomized control trials (RCT), experimental studies, Cross sectional studies 
as well as the case-control studies assessing and studying CML were excluded, as 
they would not provide incidence data. Studies report CML as secondary to other type 
of cancer or if CML had transformed from other malignancy were also excluded as 
our focus is on primary CML incidence.  
Studies that didn’t report 95% confidence interval were excluded from 
quantitative analysis (Meta-analysis) but included in Qualitative assessment 
(Systematic Review) it is not possible to pool such studies in forest plot without  CI. 
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3.4 Search Strategy 
            The search strategy was developed to include a comprehensive database 
search using broader search terms: chronic* OR chroniq* OR chronik* OR cronic* 
and myeloid* OR myelogen* OR myelitis* OR granulocytic* OR monocytic* OR 
myelocytic* and incidence OR epidemiology. Medical Subject Heading (MeSH) 
terms were used when appropriate using the above terms with a combination of ‘and
’ and ‘or’ in accordance with search engine specifications. 
 
3.5 Data bases 
The databases searched were MEDLINE (Ovid), and ProQuest. Manual search 
was conducted looking for relevant studies reported in the reference lists of the 
included papers. The titles or abstracts of these publications were reviewed and 
duplicate entries were eliminated. The database search was performed in between 
20th and 30th of February 2019.   
 
3.6 Study Records 
 
            The extracted records were reviewed by the Author according to the inclusion 
and exclusion criteria. The duplicate records were eliminated and a PRISMA flow 
chart was created [36] (Fig 2) 
 
 
3.7 Data Extraction 
 
     Data form the eligible studies were extracted by the author and collected on a 
master table. Name of the authors, year of publication, data on the time period 
covered by the study, location of the study, inclusion and exclusion criteria of the 
study, the reported population at risk, incidence or number of cases and size of 
  
11 
 
population at risk were collected. A qualitative narrative summary of the included 
studies was summarized in the result section. 
 
3.8 Risk of Bias Assessment 
            All the included studies were assessed by the author for internal and external 
validity using the criteria for bias assessment in prevalence and incidence studies [37]. 
Figure 3. The assessment of bias was conducted for all the 25 papers included in the 
quantitative analysis. The result is reported in Table 1. 
 
 
 
Figure 2. The 10 criteria used to assess bias in Table 2 (Hoy et al., 2012) 
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3.9 Data Synthesis 
             
           We pooled the quantitative data using Meta-XL version 5.3[38]. We reported 
the pooled incidence and 95% confidence intervals (CI) and explored the robustness 
of meta analyses using appropriate meta-analytical models based on the level of 
heterogeneity. Statistical heterogeneity was assessed using Cochrane Q statistic and I-
squared Statistics. 
           Most prevalence and incidence meta-analyses encounter significant 
heterogeneity. The Random Effect Model (REM) is often recommended in the 
presence of significant heterogeneity between studies, including the Cochrane 
methods groups. In addition, the main analysis using REM models. Doi and Thalib 
argued that Quality Effect Model (QEM) were ideal when there is significant 
heterogeneity is encountered. However, unlike the random-effects model which 
depends on observed between-trial heterogeneity, the model suggests adjustment 
based on measured methodological heterogeneity between studies and propose a 
simple non-iterative procedure for computing the combined effect size [39].  
            Forest plots were used to display the incidence of CML with corresponding 
95% confidence intervals. Doi’s and funnel plot created by plotting the log event rate 
against the standard error were constructed to evaluate the publication bias.  
 
3.10 Subgroup Analysis 
            As most of studies were performed on Europe and USA, Subgroup analysis by 
location was done by comparing incidence rates from Europe, USA and other 
countries studies with incidence Estimate from our study. 
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3.11 Incidence over time 
            In order to show and explain Incidence variability and see whether CML rates 
are changing over time. Estimates from each study has plotted against publication 
year as a proxy for data collection time.  
 
3.12 CML and Age 
          Included studies has reported different median age from as low as 47 to as 
high as 72 years. In order to study whether CML Incidence increases as age increases, 
median age plotted against Incidence estimates.  
 
3.13 Assessment of Heterogeneity 
            Heterogeneity in our study was assessed using the Cochrane Q statistics as 
well as Higgen’s I2 value. A p-value of <0.05 was considered significant for the 
Cochrane Q, and an I
2
 > 50% was indicative of significant heterogeneity as per the 
Cochrane guidelines this study [40]. 
            Forest plots were used to display the incidence of CML with corresponding 
95% confidence intervals. Standard funnel plot created by plotting the log event rate 
against the standard error were constructed to evaluate the publication bias.  
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Chapter 4: Results 
4.1. Search Findings flow chart 
            The total number of papers identified was 696. The flowchart below shows the 
procedure of processing the articles and identification of relevant publications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
Figure 3: Systematic search strategy flow chart 
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(n =  7) 
  
15 
 
 
4.2 Quality of the Studies 
 
            Of the 25 studies, 7 of them were rated to have high quality and 9 were of 
intermediate quality and remaining 9 were of low quality. 
 
Table1. Assessment of bias per Hoy criteria described in figure 1.  
 
 
Author \ Year 1 2 3 4 5 6 7 8 9 10 Score Risk of bias
Al-Bahar et al 1993 Yes Yes Yes No No Yes No Yes Yes Yes 7 Intermediate
Alston et al 2007 Yes Yes Yes Yes Yes No No No Yes No 6 High
Beinortas et al  2016 Yes Yes Yes Yes Yes No Yes Yes Yes Yes 9 low
Chen et al 2013 Yes Yes Yes Yes Yes Yes No No Yes Yes 8 Intermediate
Fitzmaurice et al 2017 Yes Yes Yes No No Yes No No Yes Yes 6 High
Harrison et al  2004 Yes Yes Yes No No Yes No No Yes Yes 6 High
Hoffmann et al 2015 Yes Yes Yes Yes Yes Yes Yes No Yes Yes 9 low
Höglund et al 2013 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10 Low
Hutchinson et al 2008 No Yes Yes Yes Yes No No No Yes Yes 6 High
Jayasekara et al 2009 Yes Yes Yes Yes Yes Yes No Yes Yes Yes 9 low
Maynadié et al 2010 No Yes Yes Yes Yes No No Yes Yes Yes 7 Intermediate
McNally et al  1998 Yes No No Yes Yes Yes Yes Yes Yes Yes 8 Intermediate
Nakata et al 2017 No No Yes Yes Yes Yes Yes No Yes Yes 6 High
Nguyen et al 2018 No Yes Yes Yes Yes Yes Yes Yes Yes Yes 9 low
Novak et al 2012 Yes Yes Yes Yes Yes No No Yes Yes No 7 Intermediate
Oelofse et al 2018 No Yes Yes Yes Yes Yes No Yes Yes Yes 8 Intermediate
Osca-Gelis et al 2013 No Yes Yes Yes Yes Yes No Yes Yes Yes 8 Intermediate
Osorio et al 2016 Yes Yes Yes Yes Yes No No Yes Yes Yes 8 Intermediate
Pheekoetal 2006 Yes Yes Yes Yes Yes No Yes Yes Yes Yes 9 low
Sant et al 2010 Yes Yes Yes No Yes Yes Yes Yes Yes Yes 9 low
Smith et al 2011 Yes Yes Yes No Yes Yes No Yes Yes Yes 8 Intermediate
Thielen et al  2016 Yes Yes Yes Yes Yes No Yes Yes Yes Yes 9 low
Troussard et al 2009 No Yes Yes No Yes No Yes No Yes Yes 6 High
Visser et al 2012 Yes Yes Yes No Yes No No No Yes Yes 6 High
Yamamoto et al 2007 Yes Yes Yes Yes Yes Yes Yes No Yes Yes 9 low
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4.3 Study characteristics (Systematic Review) 
           A total of 25 studies were found to fit the selection criteria. Many studies were 
excluded due to inappropriate study designs (i.e., experimental, quasi, controlled 
studies). Studies reporting leukemia other than CML as well as studies reporting 
prevalence without incidence were excluded. Studies reported CML incidence without 
confidence intervals were only used in the narrative review and not for the meta 
analysis. This is because incidence was not possible to pooled without standard error 
or confidence intervals as they needed to be weighted appropriately.  
            Of the 25 studies that we included in this review, one study did not report the 
number of CML cases. Total number of new cases of CML diagnosed in these 24 
studies were 118,292. Most of the studies covered a large geographical and 
populations but mainly were in North America and Europe. Two large studies were 
done in the United States covering a verity of states including: Detroit (Michigan), 
Atlanta (Georgia), Iowa, Utah, New Mexico, San Francisco-Oakland (California), 
Seattle Puget Sound (Washington) and Hawaii, covering more than 10% of USA 
population. Two large studies were reported from the Europe, covering more than 20 
countries.  
            One study reported CML incidence from different parts of the world and 
included more than 60,000 cases of CML. The rest of studies were national or 
regional.  These studies were analyzing CML cases occurring in Germany, Sweden, 
France (Burgundy), Spain (Girona), South - East England, UK, South Africa (Eastern 
Cape Province), Japan, Lithuania, Netherlands, Croatia, Australia, France (Basse-
Normandie), Scotland, Kuwait and Canada (Alberta). 
            Many studies reported incidence based on population-based or national 
registries, the rest was depending on the laboratory data that were confirmed the CML 
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using BCR/ABL or bone marrow findings. The studies covered the duration of time 
ranging from 1975 to 2015, but the majority of studies were after 2000, post- TKI era. 
16 studies had reported crude incidence per 100,000 populations, 14 studies had 
reported age standardized incidence per 100,000 standard populations, 8 studies 
reported both crude and standardized incidence and 4 studies reported person- year 
per 100,000. However only seven studies reported incidence with confidence interval 
that could be pooled using incidence meta-analysis.  
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Table 2. Summary of the 25 studies included in the systematic review. 
 
 
Reference\ Year Country Period No of 
cases
Median 
Age
Crude  
incidence
standardised 
incidence
Person-
year
Reported 
Population
Al-Bahar et al 
1993
Kuwiat 1979-1989 107 _ 0.5 0.8 _ 2.14  m
Alston et al 2007 Enngland 1979-2001 325 _ _ _ 0.17 _
Beinortas et al  
2016
Lithuania 2000-2013 601 62 1.28 0.87 _ 3 m
Chen et al 2013 USA 1975 -2009 13,869 66 _ 1.75 _ _
Fitzmaurice et al 
2017
Global 
incidence
2015 64000 _ _ _ 0.95 _
Harrison et al  
2004
Scotland 1999-2000 64 _ 0.64 _ _ 5 M
Hoffman et al 
2015
EUTOS 
(Europe)
2008–2012 2956 56 0.99 0.96 _ 92.5
Höglund et al 
2013
Sweden 2002–2010 779 60 0.9 _ _ 9.5 m
Hutchinson et al 
2008
 Germany 1998–2000 218 57 0.79 _ _ 9.2 m
Jayasekara et al 
2009
Australia 1982-2004 1294 65 _ 0.8 _ 4.9 m
Maynadié et al 
2010
(Burgundy, 
France)
1980-2004 141 56 0.9 _ _ 512,272
McNally et al  
1998
Uk 1984-1993 _ _ _ 0.96 _ _
Nakata et al 
2017
Japan 1993 -2010 53 _ _ 1.1 _ _
Nguyen et al 
2018
Alberta, 
Canada
2011 - 2015 _ 48 0. 7 _ 0.87 1.4 m
Novak et al 2012 Croatia 1988-2009 1122 _ _ 0.68 _ 4.4 m
Oelofse et al 
2018
Eastern Cape 
Province -
South Africa
2004 - 2013 154 47 0.24 0.34 _ 6.5 m
Osca-Gelis et al 
2013
Girona, Spain 1994-2008 102 62 1.15 0.96 _ 731, 864
Osorio et al 2016 Spain 2010 - 2012 250 54 1.08 1.04  _ 7.9 m
Pheekoetal 2006 South - East 
Eengland
1999-2000 180 65 1.72 1.1 _ 5.5 m
Sant et al 2010 Europe 
(HAEMACARE 
project)
200-2002 2468 _ 1.1 _ _ _
Smith et al 2011 UK 2004-2009 165 72 0.9 _ _ 3.6 m
Thielen et al  
2016
Netherlands 1989-2012 3585 62 _ _ 0.85 _
Troussard et al 
2009
Basse-
Normandie - 
France
1997-2004 126 56 0.9 0.79  _ 1.4 m
Visser et al 2012 Europe 
(PARECARE)
1995-2002 10047 _ 1.2 _ _ 497.5 m
Yamamoto et al 
2007
USA  1997-2002. 15686 _ _ 1.56 _ _
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4.4 Pooled Estimates 
            The Random Effect Model was carried to pool the estimate standardized 
incidence and resulted in a pooled CML incidence of 1.10 per 100,000 standard 
populations (95% CI: 0.71 – 1.70) See figure 4. As expected, significant heterogeneity 
was encountered. The I
2
 value = 98% and Q- value equals 171.48 with p <0.001.  
 
 
 
Figure 4: Forest plot of the age standardized incidence of CML under the Random-
Effect Model. 
 
 
            Further, Crude incidence was also pooled using REM.  The pooled estimate 
of the crude CML incidence was 0.72 per 100,000 populations (95% CI: 0.48 – 1.08) 
See figure 5.  Again, significant heterogeneity was encountered as indicated by the I
2
 
value = 94% and p value of the Cochrane Q was <0.001.  
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Troussard et al 2009   
Fitzmaurice et al 2017  
Nakata et al 2017  
Overall  
Q=171.48, p=0.00, I2=98%
Chen et al 2013  
    ES (95% CI)          % Weight
   0.79  (  0.64,  0.94)     24.5
   0.95  (  0.85,  1.10)     25.2
   1.10  (  0.80,  1.15)     24.6
   1.10  (  0.71,  1.70)    100.0
   1.75  (  1.72,  1.78)     25.7
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Figure 5: Forest plot of the Crude incidence of CML under the Random-Effect Model 
 
            We also carried a combined analysis including both crude and age 
standardized measures. We found the pooled estimate of the combined incidence were 
0.92 per 100,000 populations (95% CI: 0.70 – 1.22). (See figure 6). We also used 
REM for these data synthesis and significant heterogeneity was indicated by an I
2
 
value of 99% and a P value of Cochrane Q to be < 0,001. 
 
 
 
Figure 6: Forest plot of the incidence of CML under the Random-Effect Model 
 
Yasse
ES
1
Study 
Oelofse et al 2018  
Overall  
Q=34.61, p=0.00, I2=94%
Smith et al 2011  
Sant et al 2010  
    ES (95% CI)          % Weight
   0.24  (  0.12,  0.36)     22.9
   0.72  (  0.48,  1.08)    100.0
   0.90  (  0.80,  1.10)     37.5
   1.10  (  1.06,  1.15)     39.7
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    Prev (95% CI)          % Weight
   0.24  (  0.12,  0.36)      9.7
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   1.10  (  1.06,  1.15)     15.5
   1.75  (  1.72,  1.78)     15.6
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4.5 Publication bias 
            Although Hunter [41] argued classical funnel plots were not reliable for 
proportion measures. Funnel plot indicated that there appear to be publication bias 
(see Figure 7.). As the final number of included studies was reduced to be in total 7 
studies (those who reprts confidence interval), Plot shows asymmetry to the left of 
plot which confirn the bias. In additin, LFK index shows a vlue of -7.88 which 
indicate major assymetry; this is also expected for the same reasons mentioned up. 
          Such puplication bias in the study can lead to misinterpretation of its results and 
may eventually lead to imprecise conclusions. In addition, can result in misleading 
conclusions and give the impression of unfounded precision of results. 
 
 
 
Figure 7: Funnel Plot showing publication bias. 
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Figure 8: Doi Plot showing publication bias. 
 
 
4.6 CML Variation 
4.6.1 Regional Variation 
            USA and Europe were higher compared to our estimate from meta-analysis 
and other countries like Australia, Japan, Kuwait and South Africa.  
 
Table 3: Subgroup analysis by region. 
Region Incidence 
USA 1.65 
Europe 1.07 
All (Meta - analysis result) 0.92 
Others  0.69 
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4.6.2 Time Variation 
            One of our objective of this study was to assess if the CML incidence are 
increasing over time as in line with most other cancer. We plotted the estimates from 
each study against the year of publication (proxy to data collection). As can be seen in 
the figure 9, there appear to be no trend of increase or decrease in the CML incidence 
with slope of 0.0037 which confirms of not changing incidence. 
 
 
Figure 9: CML Incidence over time. 
 
 
 
4.6.3 Age Variation 
 
          The lowest reported median age of patients diagnosed with CML was 47 years. 
the plot below (figure 10) shows linear trends and association between median age 
and CML Incidence. 
 
 
 
Figure 10: CML over median age. 
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Chapter 5: Discussion 
 
 
            This study included 25 eligible studies from different countries throughout the 
world to systematically review incidence in patients with Chronic Myeloid Leukemia. 
The study revealed that The pooled estimate of incidence of CML is 0.92 per 100,000 
populations (95% CI: 0.70 – 1.22). Incidence rate estimate in our work are consistent 
with results from Sweden, England, Taiwan and EUTOS (European and Treatment, 
and Outcome study for CML)   population based study that published CML incidence 
in 20 European countries [26, 42 - 44]. In contrast, the Surveillance, Epidemiology, 
and End Result (SEER) project in the Unites States reported higher incidence rate. 
Nevertheless, SEER project include patients without laboratory confirmation which 
may contribute to include more cases of CML and affecting the whole incidence rate 
[45]. The only study in middle east was in Kuwait within the period of 1979 and 1989 
with incidence of 0.5 per 100000 populations [46].  
            The studies covered the duration of time ranging from 1975 to 2015 but the 
majority was after 2000. Studies included in the systematic review reported incidence 
in various ways, with crude, age-standardized and per person year.16 studies had 
reported crude incidence per 100,000 populations. Of them, 3 studies only entered the 
quantitative review and the rest didn’t due to non-reporting confidence interval.  The 
pooled estimate of crude incidence of CML is 0.72 per 100,000 populations (95% CI: 
0.48 – 1.08).  
            14 studies had reported age standardized incidence per 100,000 standard 
populations. Of them 4 studies only entered the quantitative review and the rest didn’t 
due to non-reporting confidence interval. The pooled estimate of crude incidence of 
CML is 1.10 per 100,000 standard populations (95% CI: 0.71 – 1.70). 8 studies 
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reported both crude and standardized incidence and 4 studies reported person- year 
per 100,000. In total, 7 studies reported incidence with confidence interval. 
            Subgroup analysis didn’t show important regional variation between Europe 
and world estimate. While when others country (Japan and South Africa) compared to 
overall incidence shows some variation away from global incidence. The variation 
with Japan and south Africa shall be attributed to inclusion criteria of those studies 
which report incidence in all age group compared to European one that include patient 
above 18 years. 
          There was no trend of increasing incidence overtime and this can be attributed 
to study limitation described below. However, we expect more cases of CML next 
years as health technology has been improving compared to old methods which mean 
more accurate and early diagnosis. in addition, cancer in general - including CML is 
currently discovered and identified much earlier due to regular test and early detection 
program in asymptomatic individual. 
            Age is one of the factors associated with variation in incidence of CML. CML 
incidence increases by age, some of these variations are due to significant differences 
in the age distributions of the investigated populations. However, also age - 
standardized incidence vary considerably as well. So such differences cannot be 
explained solely by variances in the age. Methodological factors explain these 
discrepancies; In particular, the inclusion of patients with BCR-ABL-negative 
myeloproliferative disorders may account for the higher incidence of CML in some 
registries, such as SEER reporting an incidence of 1.75/100,000, varying from 1.4 to 
2.0 between different regions within the USA. 
            The etiology of CML is essentially unknown. Ionizing radiation is the only 
established risk factor, having been linked to CML in atomic bomb survivors [5]. 
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Results from a recent population-based case-control study suggested a weak 
association between smoking and CML, but this has not yet been confirmed by other 
studies [47]. In a study based on the Swedish Cancer Registry and Multigenerational 
Registry, Bjorkholm et al. found no significant familial aggregation of CML [48]. 
            There is considerable heterogeneity in the estimates of the incidence of NEC 
across the studies included in the Meta-Analysis. This may be explained by the 
variability of the standard in health care systems, variability inclusion and exclusion 
criteria and differences in measurement methods.  
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Chapter 6: Limitation and Recommendation 
 
6.1 Limitations 
           The meta-analysis study extraction was performed by one individual, the 
principle investigator. Most of studies were registry based that have a risk of many 
limitation; Cancer registries record cancer cases, not patients. Because a patient may 
have multiple primary cancers, the same person can appear more than once in a 
registry database. In addition, data might be delayed to be recorded causing less 
number of cases and thereby affecting numerators, denominators, and incidence rate. 
Furthermore, data based on registries not always representing the national cases 
especially in the case of big countries.  
           Apart from the conceptual issues about combining heterogeneous data, 
inadequate reporting of frequency estimates limited our study; In order to pool data, 
the Systematic Error (SE) or 95% CI for each estimate are required to weight the 
estimate. Only 7stufdies of studies reported SEs or 95% CI for their corresponding 
rates. We were not able to infer SEs for another of studies where exact data on the 
numerator, denominator and duration of recruitment were not fully available. As a 
consequence, pooled estimates for systematic reviews have to be based on the ‘subset’ 
of studies, which may introduce biases. 
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6.2 Recommendation 
          Although CML cases represent 15% of all leukemia and incidence is not 
increasing over time. Our study recommends to widely adopting programs that 
investigate patient routinely in primary health settings to early identify them and start 
targeted therapy treatment (TKI) as it proves high efficiency in treating CML. The 
synthesis of incidence data has been critical for the evaluation of disease burden 
measures such as the Disability-Adjusted Life Year (DALY), a metric increasingly 
relied on for the prioritization of health care and service planning (Murray et al., 
1994). 
In addition, Further research is needed to explore how much these variations in 
incidence are due to genetic susceptibility and/or environmental etiological factors. 
Future studies may also include cohort stratification by sociodemographic 
characteristics such as ethnicity or lifestyle factors, and consider other updated 
epidemiological measures. 
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